Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

被引:259
作者
Biswas, Subhankar [1 ]
Rao, C. Mallikarjuna [1 ]
机构
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmacol, Manipal 576104, Karnataka, India
关键词
Epigenetics; Writers; Readers; Erasers; Cancer; Epigenetic drugs; PROTEIN ARGININE METHYLTRANSFERASE; SMALL-MOLECULE INHIBITOR; HISTONE LYSINE METHYLATION; TUMOR-SUPPRESSOR GENES; DOMAIN-CONTAINING PROTEINS; CHROMO BARREL DOMAIN; DE-NOVO METHYLATION; CPG-BINDING DOMAIN; TANDEM PHD FINGER; DNA METHYLATION;
D O I
10.1016/j.ejphar.2018.08.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Addition of chemical tags on the DNA and modification of histone proteins impart a distinct feature on chromatin architecture. With the advancement in scientific research, the key players underlying these changes have been identified as epigenetic modifiers of the chromatin. Indeed, the plethora of enzymes catalyzing these modifications, portray the diversity of epigenetic space and the intricacy in regulating gene expression. These epigenetic players are categorized as writers: that introduce various chemical modifications on DNA and histones, readers: the specialized domain containing proteins that identify and interpret those modifications and erasers: the dedicated group of enzymes proficient in removing these chemical tags. Research over the past few decades has established that these epigenetic tools are associated with numerous disease conditions especially cancer. Besides, with the involvement of epigenetics in cancer, these enzymes and protein domains provide new targets for cancer drug development. This is certain from the volume of epigenetic research conducted in universities and R&D sector of pharmaceutical industry. Here we have highlighted the different types of epigenetic enzymes and protein domains with an emphasis on methylation and acetylation. This review also deals with the recent developments in small molecule inhibitors as potential anti-cancer drugs targeting the epigenetic space.
引用
收藏
页码:8 / 24
页数:17
相关论文
共 250 条
[1]   G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status [J].
Agarwal, Pallavi ;
Jackson, Stephen P. .
CANCER LETTERS, 2016, 380 (02) :467-475
[2]   MG98, a Second-Generation DNMT1 Inhibitor, in the Treatment of Advanced Renal Cell Carcinoma [J].
Amato, Robert J. ;
Stephenson, Joe ;
Hotte, Sebastien ;
Nemunaitis, John ;
Belanger, Karl ;
Reid, Gregory ;
Martell, Robert E. .
CANCER INVESTIGATION, 2012, 30 (05) :415-421
[3]   The diverse functions of Dot1 and H3K79 methylation [J].
Anh Tram Nguyen ;
Zhang, Yi .
GENES & DEVELOPMENT, 2011, 25 (13) :1345-1358
[4]  
[Anonymous], NAT REV GENET
[5]  
Attar N., 2017, COLD SPRING HARB PER, V7
[6]   Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1 [J].
Avvakumov, George V. ;
Walker, John R. ;
Xue, Sheng ;
Li, Yanjun ;
Duan, Shili ;
Bronner, Christian ;
Arrowsmith, Cheryl H. ;
Dhe-Paganon, Sirano .
NATURE, 2008, 455 (7214) :822-U13
[7]   The MYST family of histone acetyltransferases and their intimate links to cancer [J].
Avvakumov, N. ;
Cote, J. .
ONCOGENE, 2007, 26 (37) :5395-5407
[8]   Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression [J].
Balasubramanyam, K ;
Altaf, M ;
Varier, RA ;
Swaminathan, V ;
Ravindran, A ;
Sadhale, PP ;
Kundu, TK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (32) :33716-33726
[9]   Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain [J].
Bannister, AJ ;
Zegerman, P ;
Partridge, JF ;
Miska, EA ;
Thomas, JO ;
Allshire, RC ;
Kouzarides, T .
NATURE, 2001, 410 (6824) :120-124
[10]   Arginine methylation: An emerging regulator of protein function [J].
Bedford, MT ;
Richard, S .
MOLECULAR CELL, 2005, 18 (03) :263-272